908 Devices Inc.
$7.3
▲
6.44%
2026-04-21 08:02:01
908devices.com
NGM: MASS
Explore 908 Devices Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$267.64 M
Current Price
$7.3
52W High / Low
$9.34 / $4.2
Stock P/E
13.73
Book Value
$3.96
Dividend Yield
—
ROCE
-16.46%
ROE
-25.77%
Face Value
—
EPS
$-0.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
172
Beta
0.53
Debt / Equity
3.22
Current Ratio
4.24
Quick Ratio
3.86
Forward P/E
-24.2
Price / Sales
4.75
Enterprise Value
$158.55 M
EV / EBITDA
-7.64
EV / Revenue
2.82
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rapid Micro Biosystems, Inc. | $2.25 | — | $103.66 M | — | -84.08% | -86.82% | $4.94 / $2.01 | $0.75 |
| 2. | Integra LifeSciences Holdings Corporation | $11.16 | — | $875.54 M | — | 0.57% | -39.9% | $17.54 / $8.7 | $13.4 |
| 3. | enVVeno Medical Corporation | $12.08 | — | $7.92 M | — | -76.16% | -56.21% | $196.7 / $8.67 | $41.36 |
| 4. | Standard BioTools Inc. | $0.97 | — | $361.83 M | — | -20.31% | -13.13% | $1.72 / $0.87 | $1.23 |
| 5. | Alphatec Holdings, Inc. | $11.55 | — | $1.68 B | — | -10.13% | -6.31% | $23.29 / $9.89 | $0.08 |
| 6. | Co-Diagnostics, Inc. | $1.67 | — | $6.02 M | — | -147.54% | -1.26% | $46.5 / $1.35 | $9.85 |
| 7. | Neogen Corporation | $9.63 | — | $2.08 B | — | -0.05% | -25.57% | $11.43 / $4.32 | $9.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.38 M | 14.01 M | 13.04 M | 11.78 M | 18.82 M | — |
| Operating Profit | -3.17 M | -5.62 M | -8.37 M | -8.53 M | -11.19 M | — |
| Net Profit | 4.17 M | -14.98 M | -13.31 M | 43.6 M | -19.45 M | — |
| EPS in Rs | 0.11 | -0.4 | -0.36 | 1.17 | -0.52 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 56.2 M | 47.75 M | 50.23 M | 46.85 M |
| Operating Profit | -25.68 M | -29.95 M | -42.65 M | -35.38 M |
| Net Profit | 19.49 M | -72.21 M | -36.4 M | -33.56 M |
| EPS in Rs | 0.52 | -1.93 | -0.97 | -0.9 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 190.07 M | 159.48 M | 202.98 M | 242.59 M |
| Total Liabilities | 46.37 M | 44.88 M | 37.49 M | 51.99 M |
| Equity | 143.7 M | 114.59 M | 165.49 M | 190.6 M |
| Current Assets | 144.56 M | 103.06 M | 173.79 M | 215.63 M |
| Current Liabilities | 34.06 M | 25.15 M | 22.55 M | 19.23 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.69 M | -30.25 M | -25.06 M | -20.93 M |
| Investing CF | 50.75 M | -46.32 M | -26.4 M | -15.81 M |
| Financing CF | -0.7 M | -0.38 M | -15.94 M | 1.18 M |
| Free CF | -24.64 M | -30.85 M | -27.1 M | -22.98 M |
| Capex | -0.95 M | -0.6 M | -2.04 M | -2.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -4.94% | 7.21% | — | — |
| Earnings Growth % | -98.37% | -8.45% | — | — |
| Profit Margin % | -151.23% | -72.47% | -71.64% | — |
| Operating Margin % | -62.73% | -84.91% | -75.52% | — |
| Gross Margin % | 51.31% | 50.41% | 55.54% | — |
| EBITDA Margin % | -52.92% | -67.74% | -67.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.